JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, J. H.
Right arrow Articles by Lin, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, J. H.
Right arrow Articles by Lin, T. H.

Blood-brain barrier permeability and in vivo activity of partial agonists of benzodiazepine receptor: a study of L-663,581 and its metabolites in rats

JH Lin, IW Chen and TH Lin

Merck Research Laboratories, West Point, Pennsylvania.

L-663,581 [FG 8205; 7-chloro-4,5-dihydro-5-methyl-3-(5-(1-methylethyl)- 1,2,4-oxadiazol-3-yl)6H-imidazo(1,5-A)(1.4)-benzodiazepine-6-one] is an investigational partial agonist of benzodiazepine receptors for possible application in the treatment of anxiety. Previous studies have shown that the drug is eliminated mainly by biotransformation in rats, dogs and monkeys. Two metabolites, mono- and bis-hydroxy analogs were demonstrated to be active in vitro. The potency of benzodiazepine receptor binding (Ki) is 3.7 nM for the parent drug, 3.3 nM for the mono-hydroxylated metabolite and 1.2 nM for the bishydroxylated metabolite, respectively. Although the metabolites are as potent as, or more so than the parent drug in vitro, they are inactive in rats in a conditioned emotional response model. This study was designed to explore the underlying mechanisms responsible for the discrepancy between in vitro and in vivo activity of the metabolites. After i.v. administration of L-663,581 or its preformed metabolites, the metabolites were cleared more slowly than the parent drug. After i.p. administration at the same dose, the areas under the curve of the metabolites were 2 to 5 times that of the parent drug. Thus, the lack of in vivo activity of the metabolites cannot be explained by the absorption and/or elimination kinetics. Brain uptake studies indicated that the permeability of the blood-brain barrier is high for L-663,581 but very poor for the metabolites; the brain extraction ratio was about 0.6 for L-663,581 and less than 0.03 for the metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 271, Issue 3, pp. 1197-1202, 12/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
J. H. Lin and A. Y. H. Lu
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Pharmacol. Rev., December 1, 1997; 49(4): 403 - 449.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics.